Alkermes plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard F. Pops
- Full Time Employees
- 2,050
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Connaught House Dublin DU Ireland D04 C5Y6
- IPO Date
- Jul 16, 1991
- CIK
- 0001520262
- Website
- alkermes.com
- Similar Companies
- Business
- Alkermes plc (Nasdaq: ALKS) develops, manufactures and commercializes treatments for central nervous system (CNS) disorders, addiction and oncology. The company offers proprietary products including Vivitrol (extended-release naltrexone injection) for alcohol and opioid use disorders; Aristada and Aristada Initio (aripiprazole lauroxil) for schizophrenia; Lybalvi (olanzapine and samidorphan) for schizophrenia and bipolar I disorder; and Alkermes' oncology portfolio featuring Nemvaleukin alfa, a novel interleukin-2 variant cytokine in clinical development for advanced solid tumors. Alkermes provides contract development and manufacturing services through its Alkermes Pharma subsidiary, specializing in drug formulation, aseptic fill-finish and particle engineering for complex injectable and inhaled therapeutics. Founded in 1987 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States and Ireland, with commercial activities focused on specialty pharmaceuticals for healthcare providers, payers and patients in neurology, addiction and cancer treatment markets. In 2024, Alkermes advanced its oncology pipeline by initiating a Phase 3 clinical trial for nemvaleukin alfa in melanoma following positive Phase 2 data; completed a strategic licensing agreement with Janssen Biotech for a novel CD38-targeting antibody-drug conjugate; and reported a $200 million milestone payment from a prior collaboration while optimizing its neuroscience portfolio through cost-saving measures amid patent expirations.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alkermes to Report Second Quarter Financial Results on July 28, 2026
Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Biotech ETF Index Surges 10% After Rebalance
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tells Investors
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes PLC (ALKS) Stock Up 4.8% but GF Value Says Overvalued -- GF Score: 76/100
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles